Fan Jin

10.9k total citations · 2 hit papers
75 papers, 2.2k citations indexed

About

Fan Jin is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Fan Jin has authored 75 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 48 papers in Oncology, 17 papers in Molecular Biology and 17 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Fan Jin's work include Cancer Immunotherapy and Biomarkers (29 papers), Genetic factors in colorectal cancer (10 papers) and Colorectal and Anal Carcinomas (8 papers). Fan Jin is often cited by papers focused on Cancer Immunotherapy and Biomarkers (29 papers), Genetic factors in colorectal cancer (10 papers) and Colorectal and Anal Carcinomas (8 papers). Fan Jin collaborates with scholars based in United States, France and Australia. Fan Jin's co-authors include Kevin Norwood, Lei Xu, Karl C. Podratz, Sean C. Dowdy, Shi-Wen Jiang, Aurélien Marabelle, Wilson H. Miller, Philippe A. Cassier, Giovanni M. Bariani and Michele Maio and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.

In The Last Decade

Fan Jin

74 papers receiving 2.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pembrolizumab in Patients With Microsatellite Instability–High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study

2022 273 citations David M. O’Malley, Giovanni M. Bariani et al. profile →
Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study

2022 240 citations Michele Maio, Paolo A. Ascierto et al. Annals of Oncology profile →

Peers

Countries citing papers authored by Fan Jin

Since Specialization

Citations

This map shows the geographic impact of Fan Jin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fan Jin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fan Jin more than expected).

Fields of papers citing papers by Fan Jin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fan Jin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fan Jin. The network helps show where Fan Jin may publish in the future.

Co-authorship network of co-authors of Fan Jin

This figure shows the co-authorship network connecting the top 25 collaborators of Fan Jin. A scholar is included among the top collaborators of Fan Jin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fan Jin. Fan Jin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Pembrolizumab in microsatellite-instability-high and mismatch-repair-deficient advanced solid tumors: updated results of the KEYNOTE-158 trial 2025 ·Nature Cancer ·Aurélien Marabelle, David M. O’Malley, Andrew Hendifar, Paolo A. Ascierto, Daniel Motola‐Kuba, Nicolas Penel, Philippe A. Cassier, Giovanni M. Bariani, Ana De Jesus‐Acosta, Toshihiko Doi, Federico Longo, Wilson H. Miller, Do‐Youn Oh, Maya Gottfried, (unknown), Fan Jin, Alexander Gozman, Michele Maio	2
2	A randomized, double-blind, phase II study of MK-4280A (coformulation of favezelimab and pembrolizumab) plus lenvatinib versus pembrolizumab plus lenvatinib among patients with previously-treated mismatch repair proficient advanced endometrial cancer 2024 ·Gynecologic Oncology ·Eugenia Girda, Vicky Makker, Christian Marth, Toon Van Gorp, Mansoor Raza Mirza, (unknown), (unknown), Roman Groisberg, Fan Jin, David M. O’Malley	1
3	Lenvatinib plus pembrolizumab for patients with previously treated, advanced, triple‐negative breast cancer: Results from the triple‐negative breast cancer cohort of the phase 2 LEAP‐005 Study 2024 ·Cancer ·Hyun Cheol Chung, Esma Saâda-Bouzid, Federico Longo, Eduardo Yáñez, Seock‐Ah Im, Eduardo Castañón, Danielle Desautels, Donna M. Graham, Javier García-Corbacho, Juanita Lopez, Corina E. Dutcus, Chinyere E. Okpara, Razi Ghori, Fan Jin, Roman Groisberg, (unknown)	4
4	Prevalence of homologous recombination biomarkers in multiple tumor types: an observational study 2024 ·Future Oncology ·Chen Cai, Elisha J. Dettman, Wei Zhou, Alexander Gozman, Fan Jin, Liam C. Lee, Yixin Ren, Heng Zhou, Răzvan Cristescu, Changxia Shao	0
5	Efficacy and safety of pembrolizumab monotherapy in patients with advanced thyroid cancer in the phase 2 KEYNOTE‐158 study 2023 ·Cancer ·Do‐Youn Oh, Alain P. Algazi, Jaume Capdevila, Federico Longo, Wilson H. Miller, (unknown), Carlos Bonilla, Hyun Cheol Chung, Tormod Kyrre Guren, Chia‐Chi Lin, Daniel Motola‐Kuba, Manisha H. Shah, Julien Hadoux, (unknown), Fan Jin, Kevin Norwood, Loïc Lebellec	31
6	A phase 2 basket study of tucatinib and trastuzumab in solid tumors with human epidermal growth factor receptor 2 alterations: Uterine and cervical cancer cohorts (SGNTUC-019, trial in progress) (1261) 2023 ·Gynecologic Oncology ·Bradley J. Monk, Fan Jin, Jorge Ramos, (unknown), David M. O’Malley	1
7	Evaluation of pembrolizumab monotherapy in patients with previously treated advanced salivary gland carcinoma in the phase 2 KEYNOTE-158 study 2022 ·European Journal of Cancer ·Caroline Even, Jean‐Pierre Delord, Katharine A. Price, Kazuhiko Nakagawa, Do‐Youn Oh, Matthew Burge, Hyun Cheol Chung, Toshihiko Doi, Marwan Fakih, Shunji Takahashi, (unknown), Fan Jin, Kevin Norwood, Aaron R. Hansen	25
8	Health-related quality of life with pembrolizumab monotherapy in patients with previously treated advanced microsatellite instability high/mismatch repair deficient endometrial cancer in the KEYNOTE-158 study 2022 ·Gynecologic Oncology ·David M. O’Malley, Giovanni M. Bariani, Philippe A. Cassier, Aurélien Marabelle, Aaron R. Hansen, A. De Jesus Acosta, Wilson H. Miller, Tamar Safra, Antoîne Italiano, Linda Mileshkin, Mayur M. Amonkar, Yao Lu, Fan Jin, Kevin Norwood, Michele Maio	9
9	Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Head and Neck Squamous Cell Carcinoma 2021 ·(unknown), (unknown), (unknown), Monika D. Polewski, (unknown), Malinka Jansson, Kenneth Emancipator, Fan Jin, Burak Gümüşçü, Joy Yang Ge, (unknown), Karina Kulangara	2
10	Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study 2021 ·The Lancet Respiratory Medicine ·Timothy A. Yap, Kazuhiko Nakagawa, Nobukazu Fujimoto, Kozo Kuribayashi, Tormod Kyrre Guren, Luana Calabrò, Ronnie Shapira‐Frommer, Bo Gao, Steven Kao, Ignacio Matos, David Planchard, Arkendu Chatterjee, Fan Jin, Kevin Norwood, Hedy L. Kindler	55
11	795MO Pembrolizumab (pembro) in patients (pts) with microsatellite instability-high (MSI-H) advanced endometrial cancer (EC): Updated results from KEYNOTE-158 2021 ·Annals of Oncology ·David M. O’Malley, Giovanni M. Bariani, Philippe A. Cassier, Aurélien Marabelle, Aaron R. Hansen, A. De Jesus Acosta, W. H. Miller, Tamar Safra, Antoîne Italiano, Linda Mileshkin, Lu Xu, Fan Jin, Kevin Norwood, Michele Maio	5
12	LBA41 LEAP-005: Phase II study of lenvatinib (len) plus pembrolizumab (pembro) in patients (pts) with previously treated advanced solid tumours 2020 ·Annals of Oncology ·Zarnie Lwin, Carlos Gomez‐Roca, Esma Saâda-Bouzid, (unknown), (unknown), S-A. Im, Eduardo Castañón, Hélène Senellart, Donna M. Graham, Martin H. Voss, Mark Doherty, Juanita Lopez, Razi Ghori, Peter Kubiak, Fan Jin, Kevin Norwood, Hyun Cheol Chung	59
13	KEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) 2018 ·Annals of Oncology ·Barbara Burtness, Kevin J. Harrington, Richard Greil, Denis Soulières, Makoto Tahara, Gilberto de Castro, Amanda Psyrri, (unknown), (unknown), Å. Bratland, Thorsten Fuereder, (unknown), Ricard Mesı́a, Nuttapong Ngamphaiboon, Tamara Rordorf, Wan Zamaniah Wan Ishak, Ananya Roy, J. Cheng, Fan Jin, Danny Rischin	97
14	342TiP Phase 3 trial of pembrolizumab as a first-line treatment in subjects with recurrent/metastatic head and neck squamous cell carcinoma: KEYNOTE-048 2015 ·Annals of Oncology ·Chung‐Jen Yen, (unknown), Ezra E.W. Cohen, Jan B. Vermorken, Kevin J. Harrington, Makoto Tahara, Joy Yang Ge, James Geib, Fan Jin, Barbara Burtness	1
15	The expression of GCN5, HDAC1 and DNMT1 in parthenogenetically activated mouse embryos 2014 ·Journal of Obstetrics and Gynaecology ·(unknown), Yanbin Li, (unknown), Fan Jin	8
16	Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial 2014 ·Annals of Oncology ·Alexander M. Menzies, Michelle T. Ashworth, S. Swann, Richard Kefford, Keith T. Flaherty, Jeffrey S. Weber, Jeffrey R. Infante, (unknown), René González, Omid Hamid, Lynn M. Schuchter, Jonathan Cebon, Jeffrey A. Sosman, Shonda M Little, Peng Sun, Gursel Aktan, Danièle Ouellet, Fan Jin, Georgina V. Long, Adil Daud	64
17	Transgenerational Glucose Intolerance With Igf2/H19 Epigenetic Alterations in Mouse Islet Induced by Intrauterine Hyperglycemia 2012 ·Diabetes ·Guolian Ding, Fangfang Wang, Jing Shu, Shen Tian, Ying Jiang, Dan Zhang, Ning Wang, Qiong Luo, Yu Zhang, Fan Jin, Peter C. K. Leung, Jian‐Zhong Sheng, He‐Feng Huang	204
18	[Expression patterns of GCN5 and HDAC1 in preimplantational mouse embryos and effects of in-vitro cultures on their expressions]. 2005 ·PubMed ·(unknown), (unknown), He Huang, (unknown), Fan Jin	2
19	Up-regulation of DNA methyltransferase 3B expression in endometrial cancers 2004 ·Gynecologic Oncology ·Fan Jin, Sean C. Dowdy, Yuning Xiong, Norman L. Eberhardt, Karl C. Podratz, Shi-Wen Jiang	57
20	Study on familial aggregation of lung cancer among women in Shanghai 1996 ·(unknown), (unknown), (unknown), Fan Jin, (unknown), (unknown)	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact